DBV Technologies Announces the Results of its 2026 Combined General Meeting
DBV Technologies announced the results of its 2026 Combined General Meeting where shareholders approved all resolutions proposed by the board. The company is focused on developing treatments for food allergies using its proprietary VIASKIN patch technology, currently conducting clinical trials on peanut allergy treatments in young children. DBV Tec…